Health ProductsInformation Update

Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer

· Published by Health Canada · Official notice

Details

Alert type: Information Update
Category: Drugs
Issue: New safety information
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

In light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, Health Canada is informing healthcare professionals and Canadians that it is undertaking a review of the drug's status.

Pioglitazone is sold in Canada under the brand name "Actos" in addition to generic forms of the drug. It is used by itself or in combination with other diabetes drugs to control blood sugar levels in diabetic patients, when diet and exercise have failed.

Post-marketing reports of bladder cancer have been reported very rarely with the use of pioglitazone. This information is included in the Canadian Product Monograph. Health Canada has been closely monitoring this potential risk, and has been reviewing all relevant studies on an ongoing basis. We are taking these studies, including their strengths and limitations, into account as we continue to monitor pioglitazone safety.

Should the on-going review identify new safety information, Health Canada will take appropriate action as necessary. This can include updating Canadians with new recommendations regarding pioglitazone and the potential risk of bladder cancer.

The benefits of pioglitazone are considered to outweigh the risks when used as directed in the Canadian Product Monograph. Patients with questions or concerns about their diabetes treatment should talk to their physician or pharmacist. 

Product Monographs are available by search of Health Canada's online Drug Product Database. Product Monographs provide detailed prescribing and safety information on a drug. Part III of the Product Monograph provides information specifically for consumers.

Report health or safety concerns

How to report side effects to health products



To report suspected adverse reaction to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a Canada Vigilance Reporting Form and send to us using one of these methods:
  • Facsimile: 1-866-678-6789
  • Internet: MedEffect Canada
  • Mail: Canada Vigilance Program
    Marketed Health Products Directorate
    Ottawa, ON, Address Locator 0701E
    K1A 0K9

Related alerts

Media enquiries

Health Canada
613-957-2983

Public enquiries

613-957-2991
1-866-225-0709
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime